Immunic (STU:10VA) Short-Term Capital Lease Obligation : €0.64 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Immunic Short-Term Capital Lease Obligation?

Immunic's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.64 Mil.

Immunic's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€0.62 Mil) to Dec. 2023 (€0.64 Mil) and increased from Dec. 2023 (€0.64 Mil) to Mar. 2024 (€0.64 Mil).

Immunic's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.36 Mil) to Dec. 2022 (€0.54 Mil) and increased from Dec. 2022 (€0.54 Mil) to Dec. 2023 (€0.64 Mil).

Immunic Short-Term Capital Lease Obligation Historical Data

The historical data trend for Immunic's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Short-Term Capital Lease Obligation Chart

Immunic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.24

0.36

0.54

0.64

Immunic Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.61	0.62	0.62	0.64	0.64

Immunic Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Immunic Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Immunic's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (STU:10VA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IMUX:USA 10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines